Cited by 44DNA and Nucleic Acid ChemistryImmunotherapy and Immune ResponsesMetal complexes synthesis and properties

Ligands stimulating antitumour immunity as the next G-quadruplex challenge

Open access
Miglietta, Giulia, Marinello, Jessica, Russo, Marco, Capranico, Giovanni·2022·Molecular Cancer

Abstract

G-quadruplex (G4) binders have been investigated to discover new anticancer drugs worldwide in past decades. As these ligands are generally not highly cytotoxic, the discovery rational was mainly based on increasing the cell-killing potency. Nevertheless, no G4 binder has been shown yet to be effective in cancer patients. Here, G4 binder activity at low dosages will be discussed as a critical feature to discover ligands with therapeutic effects in cancer patients. Specific effects of G4 binders al low doses have been reported to occur in cancer and normal cells. Among them, genome instability and the stimulation of cytoplasmic processes related to autophagy and innate immune response open to the use of G4 binders as immune-stimulating agents. Thus, we propose a new rational of drug discovery, which is not based on cytotoxic potency but rather on immune gene activation at non-cytotoxic dosage.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12943-022-01649-y

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • G4-stabilizing ligand therapies mostly rely on increased genomic instability in cancer cells to slow or stop cancer progression and cell growth.

    “which mostly rely on an increased genomic instability in cancer cells to slow or stop cancer progression and cell growth (83).”

    From G-quadruplex-mediated genomic instability drives SNVs in cancer (2024) · cites this paper as [83]

    The Background (page unavailable) says several G4 binders can arrest DNA replication, causing DNA damage and genome instability, and that past research pursued cytotoxic ligands. But the Conclusions and the section on G4 stabilization (pages unavailable) describe other mechanisms and note that cancer cells can survive binder-induced DNA breaks. The paper does not establish that G4-ligand therapies *mostly rely* on genomic instability to slow or stop cancer progression or cell growth. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Deregulated or ligand-induced G4-formation is associated with the activation of DNA-damage responses, implying that aberrant G4-formation triggers similar pathways as DNA-damage.

    “deregulated or ligand-induced G4-formation is associated with the activation of DNA-damage responses, implying that aberrant G4-formation triggers similar pathways as DNA-damage (83).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 145 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Miglietta, G., Marinello, J., Russo, M., & Capranico, G.
Affiliations
University of Bologna (IT)
Corresponding author
Capranico, Giovanni
Venue
Molecular Cancer
Published
2022-09-17
Volume
21
Issue
1
Pages
180-180
ISSN
1476-4598 (ISSN-L)
OpenAlex
W4296162137
Cited by
44
References
145
Citations by year
2026: 7 · 2025: 13 · 2024: 12 · 2023: 10 · 2022: 2
FWCI
0.96
Type
journal article
Language
en
Open access
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Associazione Italiana per la Ricerca sul Cancro (23953, IG-2019, 23032)
  • Fondazione Italiana per la Ricerca sul Cancro (23953)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords
G-quadruplex binders, antitumor immunity, low-dose drug effects, genomic instability, autophagy, innate immune response, anticancer drug discovery
MeSH terms
Antineoplastic Agents, Humans, Ligands, Neoplasms, Genomic Instability, G-Quadruplexes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review